Show simple item record

dc.contributor.authorByrne, A
dc.contributor.authorAlférez, Denis G
dc.contributor.authorAmant, F
dc.contributor.authorAnnibali, D
dc.contributor.authorArribas, J
dc.contributor.authorBiankin, A
dc.contributor.authorBruna, A
dc.contributor.authorBudinská, E
dc.contributor.authorCaldas, C
dc.contributor.authorChang, D
dc.contributor.authorClarke, Robert B
dc.contributor.authorClevers, H
dc.contributor.authorCoukos, G
dc.contributor.authorDangles-Marie, V
dc.contributor.authorEckhardt, S Gail
dc.contributor.authorGonzalez-Suarez, E
dc.contributor.authorHermans, E
dc.contributor.authorHidalgo, M
dc.contributor.authorJarzabek, M
dc.contributor.authorde Jong, S
dc.contributor.authorJonkers, J
dc.contributor.authorKemper, K
dc.contributor.authorLanfrancone, L
dc.contributor.authorMælandsmo, G
dc.contributor.authorMarangoni, E
dc.contributor.authorMarine, J
dc.contributor.authorMedico, E
dc.contributor.authorNorum, J
dc.contributor.authorPalmer, H
dc.contributor.authorPeeper, D
dc.contributor.authorPelicci, Pier G
dc.contributor.authorPiris-Gimenez, A
dc.contributor.authorRoman-Roman, S
dc.contributor.authorRueda, O
dc.contributor.authorSeoane, J
dc.contributor.authorSerra, V
dc.contributor.authorSoucek, L
dc.contributor.authorVanhecke, D
dc.contributor.authorVillanueva, A
dc.contributor.authorVinolo, E
dc.contributor.authorBertotti, A
dc.contributor.authorTrusolino, L
dc.date.accessioned2017-03-04T20:33:33Z
dc.date.available2017-03-04T20:33:33Z
dc.date.issued2017-01-20
dc.identifier.citationInterrogating open issues in cancer precision medicine with patient-derived xenografts. 2017, Nat. Rev. Canceren
dc.identifier.issn1474-1768
dc.identifier.pmid28104906
dc.identifier.doi10.1038/nrc.2016.140
dc.identifier.urihttp://hdl.handle.net/10541/620189
dc.description.abstractPatient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and under drug pressure, and the mechanisms of resistance to treatment. The ability of PDX models to predict clinical outcomes is being improved through mouse humanization strategies and the implementation of co-clinical trials, within which patients and PDXs reciprocally inform therapeutic decisions. This Opinion article discusses aspects of PDX modelling that are relevant to these questions and highlights the merits of shared PDX resources to advance cancer medicine from the perspective of EurOPDX, an international initiative devoted to PDX-based research.
dc.language.isoenen
dc.rightsArchived with thanks to Nature reviews. Canceren
dc.titleInterrogating open issues in cancer precision medicine with patient-derived xenografts.en
dc.typeArticleen
dc.contributor.departmentEurOPDX Consortium and are at the Royal College of Surgeons in Ireland, Dublin 2, Irelanden
dc.identifier.journalNature Reviews. Canceren
html.description.abstractPatient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and under drug pressure, and the mechanisms of resistance to treatment. The ability of PDX models to predict clinical outcomes is being improved through mouse humanization strategies and the implementation of co-clinical trials, within which patients and PDXs reciprocally inform therapeutic decisions. This Opinion article discusses aspects of PDX modelling that are relevant to these questions and highlights the merits of shared PDX resources to advance cancer medicine from the perspective of EurOPDX, an international initiative devoted to PDX-based research.


This item appears in the following Collection(s)

Show simple item record